Premium
Interferon lambda 4 polymorphism affects on outcome of telaprevir, pegylated interferon and ribavirin combination therapy for chronic hepatitis C
Author(s) -
Nagaoki Yuko,
Imamura Michio,
Kawakami Yoshiiku,
Kan Hiromi,
Fujino Hatsue,
Fukuhara Takayuki,
Kobayashi Tomoki,
Ono Atsushi,
Nakahara Takashi,
Naeshiro Noriaki,
Urabe Ayako,
Yokoyama Satoe,
Miyaki Daisuke,
Murakami Eisuke,
Kawaoka Tomokazu,
Tsuge Masataka,
Hiramatsu Akira,
Aikata Hiroshi,
Takahashi Shoichi,
Hayes C. Nelson,
Ochi Hidenori,
Chayama Kazuaki
Publication year - 2014
Publication title -
hepatology research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.123
H-Index - 75
eISSN - 1872-034X
pISSN - 1386-6346
DOI - 10.1111/hepr.12336
Subject(s) - ribavirin , telaprevir , pegylated interferon , medicine , interferon , virology , hepatitis c , chronic hepatitis , combination therapy , gastroenterology , immunology , virus
Aim The predictive value of the recently identified interferon‐λ ( IFNL )4 polymorphism on the outcome of telaprevir ( TVR ), pegylated interferon ( PEG IFN ) plus ribavirin ( RBV ) combination therapy for chronic hepatitis C is unknown. Methods We assessed predictive factors for sustained virological response ( SVR ) for TVR , PEG IFN plus RBV combination therapy in 283 genotype 1 chronic hepatitis C patients. IFNL 4 polymorphism ss469415590 was analyzed by I nvader assay. Results SVR rates for patients with IFNL 4 TT / TT genotype were significantly higher than for those with the IFNL 4 TT /Δ G or Δ G /Δ G genotypes (93% and 59%, respectively, P < 0.0001). In a multivariate regression analysis, prior treatment history (treatment‐naïve patients or patients who relapsed during prior treatment) (odds ratio [ OR ], 2.385; P = 0.028), rapid virological response ( OR , 6.800; P < 0.0001) and ss469415590 TT / TT genotype ( OR , 8.064; P < 0.0001) were identified as significant independent predictors for SVR . In patients with IFNL 4 TT /Δ G or Δ G /Δ G genotypes, SVR rates for non‐ RVR patients were significantly lower than RVR patients (22% and 75%, respectively, P < 0.0001). Conclusion Analysis of IFNL 4 polymorphism is a valuable predictor in patients receiving TVR triple therapy.